TY - CHAP M1 - Book, Section TI - Radical Lymphadenectomy A1 - Ducko, Christopher T. A1 - Jaklitsch, Michael T. A2 - Sugarbaker, David J. A2 - Bueno, Raphael A2 - Burt, Bryan M. A2 - Groth, Shawn S. A2 - Loor, Gabriel A2 - Wolf, Andrea S. A2 - Williams, Marcia A2 - Adams, Ann PY - 2020 T2 - Sugarbaker’s Adult Chest Surgery, 3e AB - When treating patients with non–small-cell lung cancer (NSCLC), it is important to assign an accurate clinical or pathologic stage to the disease at the time of diagnosis. This adds value to the process of selecting the most appropriate therapy for the individual patient, whether it be surgical resection, neoadjuvant chemotherapy or radiotherapy, or definitive chemoradiation. The current cancer staging convention uses the basic descriptors originally proposed by Denoix1: primary tumor (T), lymph node involvement (N), and tumor metastasis (M). The contemporary classification system was adopted worldwide in 1997, after features of the 1986 combined American Joint Committee on Cancer and International Union Against Cancer TNM staging system2 were reconciled with the 1983 American Thoracic Society statement on cancer staging. The organization responsible for updating this system is the International Association for Lung Cancer Staging, which revised the staging system in 2017.3 The value of classifying NSCLC patients according to a uniform staging system that has prognostic implications based on stage grouping is difficult to overstate. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - accesssurgery.mhmedical.com/content.aspx?aid=1170410657 ER -